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Tumor	hypoxia	is	considered	an	important	thera­
peutic	problem	since	hypoxic	tumors	are	resistant	to	
some	 forms	of	 radiochemotherapy	as	well	 as	pho­
todynamic	therapy.	Therefore,	studies	on	hypoxia	in	
solid	tumors	have	been	included	in	the	mainstream	of	
cancer	research.	Current	knowledge	on	the	subject	is	
pointing	out	at	another	alarming	aspect	of	tumor	hypo­
xia.	Hypoxia	has	been	found	to	induce	genomic	and	
proteomic	changes	in	transformed	cells,	consequently	
contributing	to	the	development	of	more	aggressive	
tumor	phenotypes	[28].
The	 imbalance	 between	 oxygen	 delivery	 and	
consumption,	present	in	majority	of	locally	advanced	
solid	tumors,	is	believed	to	result	mainly	from	ischemic	
and	diffusional	 hypoxia.	However,	 a	growing	body	
of	evidence	has	accumulated,	suggesting	 that	also	
a	reduced	oxygen	transport	capability	of	blood	and	de­
creased	oxygen	pressure	may	significantly	contribute	
to	the	adverse	effects	of	tumor	hypoxia	[5,	27–28].
Angiogenesis	is	one	of	the	most	important	mani­
festations	of	 the	aggressiveness	of	hypoxic	 tumors,	
while	hypoxia	 is	considered	a	main	driving	 force	of	
neoangiogenesis	 [27,	28].	Still,	 the	details	of	mo­
lecular	basis	of	this	relationship	remain	unknown	and	
are	intensively	investigated	[5].	Data	on	the	impact	of	
systemic	hypoxemia	on	expression	and	secretion	of	
factors	involved	in	the	induction	and	sustain	of	angio­
genesis	are	scanty	and	so	far	confusing.
A	considerable	number	of	patients	diagnosed	with	
esophagogastric	cancer	suffer	from	chronic	obstruc­
tive	pulmonary	disease	(COPD)	due	to	the	common	
etiologic	factor	—	smoking.	Smoking	is	a	recognized	
risk	factor	of	esophageal	cancers,	which,	in	associa­
tion	with	an	alcohol	abuse,	accounts	 for	more	 than	
90%	of	esophageal	squamous	cell	carcinoma	cases	
in	 the	developed	world	 [3].	Similarly,	up	 to	90%	of	
COPD	cases	results	from	smoking.	COPD	is	defined	
as	a	disease	state	with	airflow	limitation	that	is	not	fully	
reversible.	Respiratory	insufficiency,	which	may	occur	
in	COPD	patients	is	mainly	a	result	of	ventilation/perfu­
sion	mismatching	[17].	In	addition	to	common	etiologic	
factor,	the	involvement	of	vascular	endothelial	growth	
factor	A	(VEGF­A),	a	key	regulator	of	angiogenesis,	
has	been	described	in	pathogenesis	of	both	cancer	
[21]	and	COPD	[8,	16].
We	designed	our	studies	 to	 test	 the	hypothesis	
that	respiratory	insufficiency	present	in	a	number	of	
patients	with	esophagogastric	 cancers	due	 to	 the	
background	chronic	pulmonary	diseases	may	be	as­
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sociated	with	more	aggressive	tumors	on	one	side	and	
up­regulation	of	angiogenic	factors	on	the	other.
materIals and methods
Patients.	 A	 study	group	 included	81	 subjects:	
34	patients	diagnosed	with	esophagogastric	cancer	
and	47	healthy	 individuals.	Sera	 from	blood	donors	
(six	females	 and	41	males;	mean	age	44.5	 years)	
acknowledged	healthy	on	the	basis	of	routine	labora­
tory	tests	served	as	controls	and	were	obtained	from	
Regional	Center	of	Blood	Donation	and	Therapeutics,	
Wroclaw,	Poland.	Cancer	patients	(seven	females	and	
27	males;	mean	age	60	years)	were	treated	in	the	De­
partment	of	Gastrointestinal	and	General	Surgery	of	our	
institution.	All	patients	were	informed	about	the	study.	
The	stady	was	approved	with	 local	ethic	committec.	
They	were	staged	clinically	according	 to	 the	guide­
lines	of	UICC	TNM	[20]	system	on	the	basis	of	upper	
digestive	 tract	 (udt)	endoscopy	with	 the	biopsy	and	
pathologic	examination,	contrast	radiographic	studies	
of	the	udt	with	barium	or	gastrografin,	posteroanterior	
and	lateral	chest	radiography,	ultrasound	examination	
of	 the	abdominal	cavity	and	cervical	nodes,	 thorax	
and	abdominal	cavity	CT,	diagnostic	 laparotomy	and	
thoracotomy.	We	examined	25	cases	of	squamous	cell	
carcinomas	(SCC)	and	nine	cases	of	adenocarcinomas	
(ADC).	Seven	patients	were	presenting	with	disease	
stage	 II,	 14	with	stage	III	 and	13	with	stage	 IV.	The	
recruited	cancer	patients	had	a	long	history	of	heavy	
smoking.	The	analysis	of	blood	gases	was	performed	
as	a	part	of	 the	routine,	pretreatment	assessment	of	
patients’	general	condition.	Gasometric	studies	were	
conducted	on	patients	at	rest,	breathing	room	air.	Partial	
respiratory	insufficiency	(hypoxemia	without	hypercap­
nia)	was	recognized	in	19	out	of	34	cancer	patients	and	
was	related	to	the	co­existence	of	chronic	pulmonary	
disorders	(COPD).	Mean	pO2	level	in	cancer	patients	
was	61.4	mmHg,	SaO2	—	91.6%,	pCO2	—	37.4	mmHg.	
Presence	of	mild­grade	anemia	was	 recognized	 in	
19	cancer	patients.	The	 following	diagnostic	criteria	
were	applied:	systemic	hypoxemia	—	pO2	<	60	mmHg	
or	SaO2	<	90%;	anemia	—	hemoglobin	(Hb)	<	13	g/dL	or	
<	12	g/dL	in	male	and	female	patients,	respectively.
Analytical methods. VEGF­C	and	VEGF­A	con­
centrations	were	assayed	according	to	the	manufac­
turer	 instructions	by	commercially	available	double	
antibody	indirect	enzyme­linked	immunosorbent	tests	
(DASI­ELISA)	provided	by	 IBL­Hamburg,	Germany.	
Factors’	levels	were	determined	in	sera	obtained	from	
blood	by	its	clotting	for	15	minutes	at	room	tempera­
ture	and	subsequent	centrifugation	for	15	minutes	at	
3000	rpm.	All	measurements	were	duplicated.	
Statistical analyses. Data	distribution	was	ana­
lyzed	with	D’Agostino­Pearson	test	for	normality.	Levels	
of	pO2,	SaO2	and	Hb	were	distributed	normally	but	nei­
ther	raw	data	nor	log­transformed	data	on	VEGF­A	and	
VEGF­C	 levels	had	Gaussian	distribution.	Therefore,	
pO2,	SaO2	and	Hb	levels	are	presented	as	mean	values	
with	standard	error	 (SE),	while	VEGF­A	and	VEGF­C	
results	are	presented	as	median	values	with	interquar­
tile	 range	(25–75%).	The	significance	of	differences	
between	groups	was	examined	with	non­parametric	
Mann	—	Whitney	U	 test	 (two­group	comparisons)	or	
Kruskal	—	Wallis	ANOVA	rank	 test	 (multigroup	com­
parisons).	Correlation	analysis	was	conducted	with	
Spearman	or	Pearson’s	 test	 in	 respect	 to	data	 type	
and	distribution.	Differences	 in	 incidence	rates	were	
analyzed	with	Fisher’s	exact	test.	Kendal	tau	(in	2	x	2	
tables)	or	Spearman	rho	coefficients	were	calculated	
for	evaluation	of	the	strength	of	studied	relation.	All	tests	
were	two­sided	and	p	values	≤0.05	were	considered	
significant.	Statistical	analysis	was	conducted	with	
MedCalc®	version	9.2.1.0	statistical	software.
results
Patients with systemic hypoxemia had higher 
incidence rates of locally advanced tumors. We	
evaluated	whether	and	which	(if	any)	of	clinico­patho­
logical	 factors	were	associated	with	 the	presence	
of	systemic	hypoxemia	 in	a	number	of	patients	with	
esophagogastric	cancers.	The	incidence	rates	of	sys­
temic	hypoxemia	in	respect	to	tumor	histology,	disease	
TNM	stage	and	co­existence	of	anemia,	together	with	
the	strength	of	the	association	are	presented	in	Table	1	
(systemic	hypoxemia	 in	 terms	of	pO2)	and	Table	2	
(systemic	hypoxemia	in	terms	of	SaO2).	
Table 1. Evaluation of association between cancer-related variables and 
respiratory insufficiency determined in terms of decreased oxygen partial 
pressure (pO2) in esophagogastric cancer
Parameter
Incidence of hypoxemia Correlation analysis
Normox-
emic
Hypox-
emic
p value Coef-
ficient
p value
Histology:
 SCC
 ADC
Disease stage:
 II–III
 IV
Tumor extension:
 T2/T3
 T4
Regional metastasis:
 N0
 N1
Distant metastasis:
 M0
 M1
Anemia presence:
 Non-anemic
 Anemic
10
5
10
5
10
5
8
7
11
4
8
7
15
4
11
8
4
15
3
16
13
6
7
12
0.462
0.728
0.013*
0.030*
1.000
0.488
–0.138K
0.009K
(0.263S)
0.460K
(0.466S)
0.398K
0.054K
0.165K
0.237
0.474
(0.131)
<0.001*
(0.007)*
0.001*
0.679
0.179
SCC — squamous cell carcinoma; ADC — adenocarcinoma; KKendall cor-
relation coefficient; SSpearman correlation coefficient; *statistically signifi-
cant at p ≤ 0.05.
We	found	that	regardless	of	the	criteria	of	systemic	
hypoxemia,	 the	strongest	association	was	observed	
with	the	extension	of	primary	tumor,	followed	by	regional	
metastasis.	Also	mean	levels	of	pO2	and	SaO2	differed	
significantly	in	groups	of	cancer	patients	stratified	ac­
cording	to	the	extension	of	primary	tumor.	The	differ­
ences	in	pO2	and	SaO2	levels	in	respect	to	other	cancer­
related	features	were	found	insignificant	(Table	3).
Anemia did not account for the observed as-
sociation between systemic hypoxemia and the 
extension of primary tumor. Anemia	 is	one	of	the	
conditions,	which	may	account	 for	 the	occurrence	
of	systemic	hypoxemia.	But	we	did	not	observe	sig­
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nificantly	higher	incidence	rates	of	anemia	in	cancer	
patients	with	 respiratory	 insufficiency	 (see	Table	1	
and	Table	2).	Moreover,	mean	pO2	and	SaO2	 levels	
did	not	differ	 in	non­anemic	vs.	 anemic	cancer	pa­
tients	(Table	3).	Yet,	in	order	to	fully	exclude	possible	
impact	of	anemia	on	hypoxemia	 relation	 to	 the	ex­
tension	of	primary	tumor,	we	determined	whether	a	
direct	correlation	between	levels	of	pO2	or	SaO2	and	
Hb	concentration	exists.	We	also	examined	whether	
anemia	presence	was	related	 to	 the	aggressive	be­
havior	of	disease,	analyzed	in	terms	of	local	invasion	
(T),	regional	(N)	or	distant	(M)	metastasis.	We	found	
no	direct	correlation	between	Hb	and	pO2	 level	 (r	=	
0.074,	p =	0.676),	as	well	as	Hb	with	SaO2	level	(r	=	
0.104,	p =	0.557).	Anemia	was	not	related	to	clinical	
evaluation	of	cancer	T	stage	(rho	=	0.072,	p =	0.679)	
and	M	stage	(r	=	0.054,	p =	0.679),	but	was	correlated	
with	N	stage	(r	=	0.525,	p <	0.0001).
Table 2. Evaluation of association between cancer-related variables and 
respiratory insufficiency determined in terms of decreased oxygen satura-
tion (SaO2) in esophagogastric cancer.
Parameter
Incidence of hypoxemia Correlation analysis
Normo-
xemic
Hypo-
xemic p value
Coef-
ficient p value
Histology:
 SCC
 ADC
Disease stage:
 II–III
 IV
Tumor extension:
 T2/T3
 T4
Regional metastasis:
 N0
 N1
Distant metastasis:
 M0
 M1
Anemia presence:
 Non-anemic
 Anemic
18
6
16
8
13
11
10
14
17
7
10
14
7
3
5
5
1
9
1
9
7
3
5
5
1.000
0.450
0.024*
0.113
1.000
0.717
0.052K
0.156K
(0.191S)
0.409K
(0.362S)
0.308K
0.008K
–0.076K
0.694
0.205
(0.273)
<0.001*
0.037*
0.011*
0.972
0.504
SCC — squamous cell carcinoma; ADC — adenocarcinoma; KKendall cor-
relation coefficient; SSpearman correlation coefficient; *statistically signifi-
cant at p ≤0.05.
Table 3. Relation of mean levels of oxygen partial pressure (pO2) and 
oxygen saturation (SaO2) to cancer-related features in esophagogastric 
cancers
Parameters pO2 levelmmHg p value
SaO2 level
% p value
Histology:
 SCC
 ADC
Disease stage:
 II/III
 IV
Tumor extension:
 T2/T3
 T4
Regional metastasis:
 N0
 N1
Distant metastasis:
 M0
 M1
Anemia presence:
 Non-anemic
 Anemic
60.6 ± 2.0
63.6 ± 4.4
63.2 ± 2.3
58.4 ± 2.9
66.6 ± 2.6
57.7 ± 2.3
64.5 ± 2.8
59.9 ± 2.4
62.0 ± 2.1
59.8 ± 3.6
60.6 ± 2.5
62.0 ± 2.6
0.479
0.204
0.015*
0.243
0.592
0.713
91.5 ± 0.6
91.6 ± 1.7
92.2 ± 0.7
90.6 + 1.1
93.5 ± 0.6
90.2 ± 0.9
93.2 ± 1.0
90.8 ± 0.8
91.6 ± 0.8
91.4 ± 1.2
91.5 ± 1.1
91.6 ± 0.8
0.952
0.244
0.011*
0.071
0.892
0.913
SCC — squamous cell carcinoma; ADC — adenocarcinoma; *statistically 
significant at p ≤ 0.05.
VEGF-A, but not VEGF-C, was more elevated in 
esophagogastric cancer patients with systemic 
hypoxemia. We	found	that	differences	 in	circulating	
VEGF­A	 levels	between	healthy	subjects	and	cancer	
patients	with	and	without	systemic	hypoxemia,	both	
when	determined	in	terms	of	pO2	(p	<	0.0001)	or	SaO2	
(p	<	0.0001),	were	significant.	A	strong	tendency	to­
wards	higher	VEGF­A	concentrations	in	hypoxemic	vs.	
normoxemic	cancer	patients	could	be	observed	(Fig.	1).	
The	strength	of	the	relation	between	VEGF­A	levels	and	
the	presence	of	hypoxemia	was:	rho	=	0.335,	p =	0.054,	
when	pO2	was	applied	as	the	criterion,	and	rho	=	0.270,	
p =	0.121	in	case	of	SaO2.	The	tendency	towards	direct	
correlation	between	VEGF­A	concentration	and	pO2	or	
SaO2	levels	was	rather	weak:	rho	=	–0.203,	p =	0.243	
and	rho	=	–0.206,	p =	0.237,	respectively.
fig. 1. Comparison	of	 serum	 levels	of	 vascular	endothelial	
growth	factor	A	(VEGF­A)	in	healthy	individuals	and	cancer	pa­
tients	without	 and	with	 systemic	hypoxemia.	A.	 respiratory	
insufficiency	in	terms	of	oxygen	partial	pressure.	B.	respiratory	
insufficiency	in	terms	of	oxygen	saturation
Boxes	represent	interquartile	range,	bars	inside	boxes	—	me­
dians,	whiskers	—	5	and	95	percentil;	*statistically	significant	
at	p	≤0.05;	**statistically	significant	at	p ≤	0.1;	CP	—	cancer	
patients.
The	differences	between	serum	levels	of	VEGF­C	
between	controls	and	cancer	patients	with	and	with­
out	systemic	hypoxemia	were	found	significant	(p	<	
0.0001	for	both	pO2	and	SaO2)	as	well.	However,	there	
was	no	difference	in	circulating	VEGF­C	between	non­
hypoxemic	and	hypoxemic	cancer	patients	 (Fig.	2).	
Accordingly,	no	 tendency	 towards	direct	correlation	
between	circulating	VEGF­C	and	the	presence	of	hy­
poxemia	was	found:	rho	=	–0.118,	p =	0.496	(for	pO2	
as	hypoxemia	criterion)	and	rho	=	–0.018,	p =	0.917	
(for	SaO2	as	hypoxemia	criterion).	Similarly,	concen­
trations	of	circulating	VEGF­C	were	not	related	to	the	
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levels	of	pO2	(rho	=	0.066,	p =	0.704)	or	SaO2	(rho	=	
0.061,	p =	0.724).
fig. 2. Comparison	of	 serum	 levels	of	 vascular	endothelial	
growth	factor	C	(VEGF­C)	in	healthy	individuals	and	cancer	pa­
tients	without	 and	with	 systemic	hypoxemia.	A.	 respiratory	
insufficiency	in	terms	of	oxygen	partial	pressure.	B. respiratory	
insufficiency	in	terms	of	oxygen	saturation
Boxes	represent	interquartile	range,	bars	inside	boxes	—	me­
dians,	whiskers	—	5	and	95	percentil; *statistically	significant	
at p ≤ 0.05; **statistically	significant	at	p	≤	0.1;	CP	—	cancer	
patients.
Circulating VEGF-A and VEGF-C levels are 
elevated in locally advanced tumors. We	evalua­
ted	VEGF­A	and	VEGF­C	relation	with	 the	extension	
of	primary	tumor.	We	found	that	serum	VEGF­A	level	
was	significantly	higher	 in	T4	cancers	as	compared	
with	less	advanced	ones	(Fig.	3)	and	that	circulating	
VEGF­A	concentration	also	directly	correlated	with	
tumor	extension:	 rho	=	0.648,	p <	0.001.	Similarly,	
serum	VEGF­C	concentration	was	higher	 in	 locally	
more	advanced	tumors	(see	Fig.	3),	but	no	direct	cor­
relation	between	parameters	was	found:	rho	=	0.227,	
p =	0.191.
Circulating	VEGF­A	exhibited	tendency	to	be	up­
regulated	also	 in	cancers	metastasizing	 to	 regional	
lymph	nodes.	Median	serum	VEGF­A	levels	in	N0	can­
cers	was	327	pg/ml	(97–356)	vs.	372	pg/ml	(198–652)	
in	N1	cancers	 (p =	0.066).	Median	serum	concen­
tration	of	VEGF­C	 in	N0	cancers	was	15.96	ng/ml	
(13.79–18.17)	vs.	20.05	ng/ml	 (13.83–25.72)	 in	N1	
cancers	(p =	0.167).	
The	 levels	of	circulating	VEGF­A	were	correlated	
neither	with	Hb	concentration	(r	=	0.052,	p =	0.767)	
nor	with	anemia	presence	(r	=	0.151,	p =	0.385).	 In	
turn,	serum	VEGF­C	levels	tended	to	be	related	with	
anemia	presence	 (r	=	0.341,	p =	0.050),	but	 there	
was	no	direct	correlation	between	VEGF­C	and	Hb	
(r	=	–0.164,	p =	0.347).
fig. 3. Relation	of	serum	levels	of	vascular	endothelial	growth	
factors	with	 the	extension	of	primary	 tumor	 (T).	A.	 vascular	
endothelial	growth	 factor	A	 (VEGF­A).	B.	vascular	endothelial	
growth	factor	C	(VEGF­C)
Boxes	represent interquartile	range,	bars	inside	boxes	—	me­
dians,	whiskers	—	5	and	95	percentil;	*statistically	significant	at	
p	≤	0.05;	**statistically	significant	at	p	≤	0.1.
dIscussIon
We	hypothesized	 that	 esophagogastric	 tumors	
from	patients	suffering	from	respiratory	insufficiency	in	
course	of	background	chronic	obstructive	pulmonary	
disease	may	behave	more	aggressively	 than	 those	
from	patients	with	cancer	disease	alone.	The	proba­
bility	of	enhanced	aggressiveness	in	this	subgroup	of	
cancer	patients	 together	with	possible	 involvement	
of	angiogenesis	mediators	have	not	been	addressed	
yet.	Indeed,	our	results	demonstrated	that	COPD­re­
lated	hypoxemia	in	esophagogastric	cancer	patients	
was	associated	with	higher	incidence	rates	of	locally	
advanced	 tumors	and	 lymph	node	metastasis.	The	
mean	levels	of	pO2	and	SaO2	were	significantly	lower	
in	T4	cancer	patients	than	in	those	with	less	advanced	
tumors	as	well.	We	also	showed	that	a	key	regulator	
of	angiogenesis,	vascular	endothelial	growth	factor	A	
(VEGF­A),	might	be	involved.
Our	findings	seem	to	be	important	from	clinical	point	
of	view.	Tumor	hypoxia	favors	cancer	aggressiveness,	
angiogenesis	and	metastasis,	and	consequently	is	as­
sociated	with	poorer	prognosis	regardless	of	treatment	
strategy	[28].	Yet,	the	current	methods	of	measuring	the	
oxygenation	status	in	tumor	tissue	are	invasive	and	not	
applicable	in	clinical	practice,	while	reliable	surrogate	
markers	are	still	being	searched	[22].	We	showed	that	
presence	of	systemic	hypoxemia	in	cancer	patients	was	
associated	with	increased	extension	of	primary	tumors	
as	well	as	with	higher	rates	of	regional	metastasis.	On	
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this	basis,	 it	can	be	suggested	 that	co­existence	of	
systemic	hypoxemia	may	guide	the	selection	of	patients	
with	more	aggressive	 tumors,	who	probably	would	
not	benefit	 from	oxygen­based	 treatment	strategies	
and	may	help	in	directing	their	further	management.	It	
may	also	facilitate	the	selection	of	patients	who	are	at	
higher	risk	of	disease	recurrence	also	when	treated	with	
surgery	alone.	This	seems	to	be	especially	important	in	
esophageal	cancers	characterized	by	reduced	overall	
survival	rates	in	comparison	with	other	solid	tumors	and	
distinguished	by	high	recurrence	rates	(up	to	79%	after	
curative	resection)	with	lymph	node	metastasis	being	a	
common	pattern	[11,	26].	
We	also	hypothesized	that	the	presence	of	COPD­
related	respiratory	insufficiency	in	cancer	patients	may	
be	associated	with	more	elevated	secretion	of	pro­
angiogenic	 factors	as	compared	 to	cancer	patients	
without	hypoxemia.	The	 rationale	was	 that	hypoxia	
alters	gene	expression	in	a	way	that	enables	the	trans­
formed	cells	to	overcome	oxygen	deprivation	mainly	by	
hypoxia­induced	transcription	factor	HIF­1α.	In	turn,	
HIF­1α	activates	a	plethora	of	genes,	VEGF-A,	being	
one	of	the	strategic	targets	[1].	Also	VEGF-C	has	been	
reported	 to	be	up­regulated	 in	 response	 to	hypoxia	
[18].	Accordingly,	we	found	that	serum	levels	of	VEGF­
A	tended	to	be	more	elevated	in	cancer	patients	with	
respiratory	 insufficiency	as	compared	 to	 those	with	
cancer	disease	alone.	Moreover,	similarly	to	systemic	
hypoxemia,	circulating	levels	of	VEGF­A	were	strongly	
related	to	the	extension	of	primary	tumor.	Therefore,	
it	is	tempting	to	speculate	that	the	impact	of	systemic	
hypoxemia	on	tumor	local	advancement	is	realized	by	
oversecretion	of	VEGF­A.	
The	 impact	of	systemic	hypoxemia	on	up­regula­
tion	of	angiogenesis	mediators	has	been	controver­
sially	discussed	in	the	recent	literature.	The	majority	of	
limited	studies	concerned	the	conditions	 induced	by	
exercise	and/or	high­altitude,	or	nocturnal	episodes	
of	hypoxemia	 in	course	of	sleeping	disorders.	These	
reports	were	entirely	 focused	on	VEGF­A,	but	 their	
results	have	been	exceedingly	confusing.	While	some	
authors	reported	the	elevation	of	circulating	VEGF­A	in	
response	to	altitude­related	hypoxemia	[29]	or	the	oc­
currence	of	acute	mountain	sickness	[24],	yet	without	
correlation	between	VEGF­A	concentration	and	pO2	or	
SaO2	levels,	the	others	observed	the	adverse	effect	of	
VEGF­A	down­regulation	[4].	Similarly	to	the	latter	find­
ing,	the	reduction	of	oxygen	saturation	in	healthy	men	
under	experimental	conditions	caused	the	decrease	in	
VEGF­A	level,	as	reported	by	Oltmanns	et	al.	[14].
Contrary	to	high	altitude­related	hypoxemia,	night­
time	hypoxemia	in	course	of	obstructive	sleep	apnea	
seems	to	be	associated	with	the	up­regulation	of	cir­
culating	VEGF­A	[6,	10,	19,	23]	and	to	be	significantly	
correlated	with	the	degree	of	nocturnal	desaturation	
[19,	23].	Yet,	Valipour	et	al.	[25]	failed	to	confirm	the	
relation	of	circulating	VEGF­A	to	night­time	hypoxemia	
in	patients	with	sleep	disorder.
Our	 results	 in	 part	 corroborate	 the	 findings	of	
limited	studies	on	changes	in	VEGF­A	concentration	
related	to	systemic	hypoxia	in	cancer.	Matsuyama	et	
al.	 [13]	 reported	 that	serum	 levels	of	VEGF­A	were	
higher	in	lung	cancer	patients	with	systemic	hypoxemia	
as	compared	to	patients	with	normoxemia.	Moreover,	
the	authors	observed	a	direct	negative	correlation	
between	VEGF­A	 concentration	 and	 the	 levels	 of	
oxygen	partial	pressure.	In	turn,	Ono	et	al.	[15]	found	
that	VEGF­A	is	more	strongly	expressed	in	colorectal	
cancer	tissue	from	hypoxemic	patients	and	that	 the	
level	of	VEGF­A	expression	adversely	correlated	with	
systemic	pO2.	These	authors	reported	systemic	pO2	to	
be	an	independent	factor	influencing	VEGF­A	content	
in	colorectal	cancer	tissue.	
We	also	evaluated	whether	VEGF­C,	 regarded	as	
the	most	 important	mediator	of	 lymphangiogenesis,	
yet	with	angiogenic	potential	as	well,	was	affected	by	
systemic	hypoxemia.	Especially	 that	we	observed	a	
tendency	 towards	higher	 incidence	rates	of	cancers	
metastasizing	to	regional	 lymph	nodes	 in	cancer	pa­
tients	with	respiratory	insufficiency.	The	up­regulation	
of	 tissue	expression	 [2,	12]	and	elevation	of	serum	
levels	[9]	of	VEGF­C	together	with	factor’s	relation	to	
regional	metastasis	have	previously	been	reported	in	
esophageal	cancer.	Moreover,	hypoxia	through	HIF­1α	
has	recently	been	linked	to	lymphatic	metastasis	in	this	
cancer	type	via	VEGF­C	up­regulation	[7].	Yet,	we	failed	
to	show	VEGF­C	overexpression	in	cancer	patients	with	
respiratory	insufficiency.	The	elevation	of	factor’s	level	
in	cancers	metastasizing	to	regional	lymph	nodes	was	
not	significant	in	this	group	of	patients.	It	can	be	a	result	
of	relatively	small	number	of	observations.	However,	it	
can	not	be	excluded	that	the	relation	of	systemic	hypox­
emia	to	lymph	node	metastasis	observed	here	may	be	
mediated	by	other	lymphangiogenic	factors.
Anemia	may	account	for	the	presence	of	systemic	
hypoxemia	on	one	side	and	up­regulation	of	angio­
genic	factors	on	the	other	[28].	Our	results	showed,	
however,	 that	 at	 least	 in	 population	 studied	here,	
the	anemia	presence	did	not	mediate	 the	observed	
relationships	between	hypoxemia,	 cancer	 clinico­
pathological	 variables	and	angiogenesis	mediators.	
Lack	of	correlation	between	VEGF­A	and	Hb	reported	
in	this	paper	is	in	agreement	with	our	previous	findings	
(manuscript	 submitted)	 ­	we	have	observed	a	 rise	
in	VEGF­A	 level	only	when	Hb	 level	dropped	below	
11	g/dL,	while	anemia	 in	currently	 studied	patients	
was	of	a	mild	grade.	
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Влияние  системной гипоксемии на агрессиВность 
заболеВания и содержание циркулирующих 
фактороВ роста эндотелия сосудоВ а и с у больных 
гастроэзофагальным раком с хронической 
респираторной недостаточностью
Цель: �� ������� � ������� ������������������ ��������� �������������, ������������� ������������ �������� �������������������           
������ ����д��� �� ���п���������й ��д������������� �� п��ц���� �������������� �����у���������� ��������� �������������, ����-
��� п��дш�����у�� ���у. ����������� ���п��������� ������ �������� �� п��������у�� ���������ц���� �пу��������й ������ �� ��������й            
���������� �пу���������� ���������������. ������� п��дп���������, ��� у �������� ���������������� п������� � ���п���������й          
��д�������������� ����������� ���п��������� ������ ���� �������� � п����ш����й ����������������� �пу���������� п��ц����, � 
�д��й �������, �� п����ш������ у�������� ������������� ��������� �� � д�у��й. Методы: ��д�������� ��������� ����� ��д�-    
������ ���уд��� A �� C �VEGF�� �п��д������ ������у���������������� �����д����� у п�ц�������� � ������������������� ������ �� ����               
���п���������й ��д������������� �� п��ц���� �������������� �����у���������� ������������� �������� ����� �� ���у�������� ���������, 
� ����� у �д�������� д�������. ����������������� д����� ������������� �� ��д�������� ������������� �� ���������������� �� �������������           
������������������, ����у�� TNM �� у������ VEGF A �� C.        Результаты: у �������� � ����������й ���п���������й ������� п����������       
�����������������й ���� ���ш�. ���ц�������� д��������� ��������д� �� ���������� ������� ��������д��� ������������ �������� у           
п�ц�������� � ����������й T4. �����ш����� ��д�������� ц����у����у������ VEGF A, �� �� C, ����� ��������� у �������� � ���п��-              
�������й ��д��������������, ���� ��� ���. ��д�������� VEGF ��������������� � ��������� п���������й �пу������.        Выводы: ��ш�� 
���у������ п�����������, ��� ����������� ���п��������� у п�ц�������� � ������������������� ������ �������� � у�������������� ������� 
п���������й �пу������, �� ����й ������ ������ ���� �п����д����� п����ш������� ��д�������� ц����у����у������ VEGF A. 
Ключевые слова: ���п���������, �����������������й ���, �����������, VEGF-A, VEGF-C, COPD, ���п���������� ��д����-        
��������.
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